Has anyone standardized a preseason medication reconciliation with a built-in TUE audit? I’m piloting a 15-minute check using Global DRO plus NDC barcode scans in clinic and want benchmarks on alert specificity, especially around inhaled beta-2 agonist dose limits and the [redacted]/mL pseudoephedrine urine threshold, so we minimize adverse event risk, avoid unnecessary TUEs, and stay clean with ADAMS submissions.
I’ve built a similar 15‑min intake with Global DRO + NDC, and , alert spam around inhaled beta‑2s drives me nuts. What helped was normalizing to delivered dose via RxNorm, using a “soft” alert at about 80% and a “hard” at 100% of WADA limits, and adding a pseudoephedrine step that asks last dose/time and hydration to estimate urine risk before triggering a TUE prompt. I map limits straight from WADA here: The Prohibited List | World Anti Doping Agency — what specificity are you seeing on albuterol vs formoterol?
I’d add an in‑ vs out‑of‑competition toggle and a SIG parser that collapses combo inhalers to active‑moiety delivered dose via RxNorm, then use soft vs hard flags to tame β2 alert noise. For pseudoephedrine, tie the rule to formulation (IR vs ER) and collection context, and surface a one‑click “why” that cites WADA TUE guidance: https://www.wada-ama.org/en/resources/therapeutic-use-exemption-tue. @emmaw_92 have you tracked how many hard flags still resolved without a TUE after this kind of normalization?